Rameen Beroukhim

Broad Institute — United States

Medicine · Health Sciences

145h-index126.5kcitations889works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(220), Cancer Genomics and Diagnostics(206), RNA modifications and cancer(64), Epigenetics and DNA Methylation(60), Protein Degradation and Inhibitors(49)

Publications827 total

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
Neuro-Oncology·2025
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors
Neuro-Oncology Advances·2025Open Access
Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
Neuro-Oncology·2025Open Access
CSIG-29. INVESTIGATING THE ROLE OF CDKN2B IN GLIOBLASTOMA
Neuro-Oncology·2025Open Access
IMG-21. Prognostic significance of contrast enhancement in newly diagnosed grade 2 <i>IDH</i> -mutant glioma
Neuro-Oncology·2025
DISP-30. Impact of distance traveled for clinical trial participation on clinical outcomes in patients with glioblastoma
Neuro-Oncology·2025Open Access
NCOG-14. Deficits in Gait Quantified by Large Language Model-derived NANO Scores Predict Survival in High-grade Glioma
Neuro-Oncology·2025Open Access
CSIG-36. LEVERAGING GENOMIC ALTERATIONS IN GLIOBLASTOMA MULTIFORME
Neuro-Oncology·2025Open Access
DDDR-39. Untangling MEK inhibitor resistance in DMG-MAPK using coupled lineage tracing and single cell RNA sequencing
Neuro-Oncology·2025Open Access
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Science Translational Medicine·2025· 7 cited
Abstract A014: Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology
Cancer Research·2025
Abstract B041: Defining essential PPM1D-regulated DNA damage response phosphosites in diffuse midline gliomas
Cancer Research·2025
Abstract A008-PR002: Membrane localization mediated by BRAF fusion partners is necessary for transformation of human neural stem cells
Cancer Research·2025
page 1 of 42Next →

Frequent Co-authors

Gad Getz(29), Matthew Meyerson(19), Stacey Gabriel(18), Reanne Bowlby(17), Andrew D. Cherniack(17), Rehan Akbani(16), Jay Bowen(14), Miruna Balasundaram(13), Juok Cho(13), Steven E. Schumacher(13), John A. Demchok(12), Eric Chuah(12), Lynda Chin(12), Adrian Ally(11), Denise Brooks(11), Scott Frazer(11), Levi A. Garraway(11), Hui Shen(10), Michael S. Lawrence(10), Kristian Cibulskis(10)